share_log

EyePoint Pharmaceuticals | DEFA14A: Others

EyePoint Pharmaceuticals | DEFA14A: Others

EyePoint Pharmaceuticals | DEFA14A：其他
美股sec公告 ·  04/27 04:06
牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) on April 26, 2024. The materials are related to a proxy statement under Schedule 14A of the Securities Exchange Act of 1934. This filing, indicated by the form DEFA14A, is an amendment that includes further materials but does not require an additional filing fee. The document was filed by EyePoint Pharmaceuticals as the registrant and does not involve any third party filers. The nature of the additional materials was not specified in the announcement.
EyePoint Pharmaceuticals, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) on April 26, 2024. The materials are related to a proxy statement under Schedule 14A of the Securities Exchange Act of 1934. This filing, indicated by the form DEFA14A, is an amendment that includes further materials but does not require an additional filing fee. The document was filed by EyePoint Pharmaceuticals as the registrant and does not involve any third party filers. The nature of the additional materials was not specified in the announcement.
EyePoint Pharmicals, Inc.已於2024年4月26日向美國證券交易委員會（SEC）提交了明確的補充材料。這些材料與1934年《證券交易法》附表14A下的委託書有關。DEFA14A 表格所示，該申請是一項修正案，包括更多材料，但不需要額外的申請費。該文件由EyePoint Pharmicals作爲註冊人提交，不涉及任何第三方申報人。公告中沒有具體說明額外材料的性質。
EyePoint Pharmicals, Inc.已於2024年4月26日向美國證券交易委員會（SEC）提交了明確的補充材料。這些材料與1934年《證券交易法》附表14A下的委託書有關。DEFA14A 表格所示，該申請是一項修正案，包括更多材料，但不需要額外的申請費。該文件由EyePoint Pharmicals作爲註冊人提交，不涉及任何第三方申報人。公告中沒有具體說明額外材料的性質。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。